14-day Premium Trial Subscription Try For FreeTry Free

Aridis Pharmaceuticals Inc. Stock Insider Power

Based on the 99 latest insides trades, we have calculated the insider power to be positive at 48.61. In total, the insiders bought 2 502 116 and sold 457 320 ARDS shares in the last 99 trades.

Insider Power

(Last 99 transactions)
48.61
Buy 2 502 116 Shares
Sell 457 320 Shares

Historical Insider Trades

Date Type Action Person Amount
Sep 18, 2023 Stock Options Buy Hamilton John F 15 000
Sep 18, 2023 Stock Options Buy Windham-bannister Susan Richards 15 000
Sep 18, 2023 Stock Options Buy Patzer Eric 15 000
Sep 18, 2023 Stock Options Buy Truong Vu 30 000
Sep 18, 2023 Stock Options Buy Jafri Hasan 20 000
Jun 05, 2023 Common Stock Buy Patzer Eric 12 000
Jun 05, 2023 Restricted Stock Units Sell Patzer Eric 12 000
Jun 05, 2023 Restricted Stock Units Sell Hamilton John F 5 000
Jun 05, 2023 Common Stock Buy Hamilton John F 5 000
Jun 05, 2023 Common Stock Buy Truong Vu 15 000
Jun 05, 2023 Restricted Stock Units Sell Truong Vu 15 000
Jun 05, 2023 Restricted Stock Units Sell Windham-bannister Susan Richards 5 000
Jun 05, 2023 Common Stock Buy Windham-bannister Susan Richards 5 000
Jun 05, 2023 Common Stock Buy Jafri Hasan 10 000
Jun 05, 2023 Restricted Stock Units Sell Jafri Hasan 10 000
Jun 05, 2023 Common Stock Buy Kurland Fred 4 000
Jun 05, 2023 Restricted Stock Units Sell Kurland Fred 4 000
May 04, 2023 Stock Options Buy Patzer Eric 30 000
May 04, 2023 Stock Options Buy Hamilton John F 15 000
May 04, 2023 Stock Options Buy Truong Vu 100 000
May 04, 2023 Stock Options Buy Windham-bannister Susan Richards 15 000
May 04, 2023 Stock Options Buy Jafri Hasan 25 000
May 04, 2023 Stock Options Buy Kurland Fred 10 000
Dec 08, 2022 Common Stock, par value $0.0001 per share Buy Cystic Fibrosis Foundation 0
Dec 05, 2022 Restricted Stock Units Buy Truong Vu 30 000
Click to get the best stock tips daily for free!

About Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals. Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-32... ARDS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT